Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

Altered Niche Interactions of Leukemia Stem Cells In a Chronic Phase Chronic Myelogenous Leukemia (CML) Transgenic Mouse Model.

Bin Zhang, Yin Wei Ho, Qin Huang, M.D., Ph.D., Claudia Huettner, Ravi Bhatia, MD

Blood (2010) 116 (21): 1212.

https://doi.org/10.1182/blood.V116.21.1212.1212

Published: 2010

Journal Articles

FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.

Joshua Oaks, BS, Paolo Neviani, PhD, A. Mukhopadhyay, Ramasamy Santhanam, PhD, Y. Ma, Charlene Mao, Guido Marcucci, MD, Ching-Shih Chen, Jorge Cortes, MD, Michael A. Caligiuri, M.D., Peter Hokland, Sr., Claudia Huettner, PhD, Steffen Koschmieder, MD, Jose Cancelas, MD, PhD, Roger Briesewitz, PhD, Ravi Bhatia, MD, Denis-Claude Roy, MD, Besim Ogretmen, PhD, Danilo Perrotti, MD, PhD

Blood (2009) 114 (22): 3259.

https://doi.org/10.1182/blood.V114.22.3259.3259

Published: 2009

Journal Articles

Blockade of IL-23 Signaling Results in Targeted Protection of the Colon and Allows for Separation of Graft Versus Host and Graft Versus Leukemia Effects.

Rupali Das, Ph.D., Richard Komorowski, M.D., Martin Hessner, Ph.D., Hariharan Subramaniam, PhD, Daniel J Cua, PhD, Claudia Huettner, PhD, William R. Drobyski, MD

Blood (2009) 114 (22): 231.

https://doi.org/10.1182/blood.V114.22.231.231

Published: 2009

Journal Articles

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Blood (2009) 114 (22): 855.

https://doi.org/10.1182/blood.V114.22.855.855

Published: 2009

Journal Articles

Characterization of Leukemia-Initiating Cells in a Transgenic Model of Chronic Phase Chronic Myelogenous Leukemia (CML).

Bin Zhang, MD, PhD, Yin Wei Ho, Sung-UK Lee, PhD, Takahiro Maeda, MD, PhD, Claudia Huettner, PhD, Ravi Bhatia, MD

Blood (2009) 114 (22): 858.

https://doi.org/10.1182/blood.V114.22.858.858

Published: 2009

Journal Articles

Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate.

Bin Zhang, MD, PhD, Adam Campbell Strauss, Su Chu, MD, Yin Wei Ho, David S. Snyder, MD, Claudia Huettner, PhD, Lenny Shultz, Tessa L Holyoake, PhD, Ravi Bhatia, MD

Blood (2009) 114 (22): 190.

https://doi.org/10.1182/blood.V114.22.190.190

Published: 2009

Journal Articles

BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells.

Jason Harb, PhD, Paolo Neviani, PhD, Claudia Huettner, PhD, Guido Marcucci, MD, Danilo Perrotti, MD, PhD

Blood (2009) 114 (22): 191.

https://doi.org/10.1182/blood.V114.22.191.191

Published: 2009

Journal Articles

Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals

Paolo Neviani, PhD, Ramasamy Santhanam, Ph.D, Yihui Ma, B.S., Guido Marcucci, MD, John C. Byrd, MD, Ching-Shih Chen, Ph.D, Jorge Cortes, MD, Michael A. Caligiuri, MD, Claudia Huettner, PhD, Ravi Bhatia, MD, Denis-Claude Roy, MD, Danilo Perrotti, MD, PhD

Blood (2008) 112 (11): 189.

https://doi.org/10.1182/blood.V112.11.189.189

Published: 2008

NARROW

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Altered Niche Interactions of Leukemia Stem Cells In a Chronic Phase Chronic Myelogenous Leukemia (CML) Transgenic Mouse Model.

FTY720 but Not Its Immunosuppressive Phosphorylated Form FTY720-P Exerts Anti-Leukemic Activity towards Ph(+) and Ph(−) Myeloproliferative Disorders through Reactivation of the PP2A Tumor Suppressor.

Blockade of IL-23 Signaling Results in Targeted Protection of the Colon and Allows for Separation of Graft Versus Host and Graft Versus Leukemia Effects.

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Characterization of Leukemia-Initiating Cells in a Transgenic Model of Chronic Phase Chronic Myelogenous Leukemia (CML).

Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate.

BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells.

Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only